Cancer, diabetes and blood pressure treatment may become a little cheaper, following a ceiling being fixed on prices of 56 Schedule-I formulations.

Products from Abbott Healthcare, Alkem Laboratories, Bicon, Novartis, Cipla, and Lupin are some of those which come under the Government’s latest price fixing/revision exercise, according to notifications by the National Pharmaceutical Pricing Authority (NPPA).

The regulatory authority has also “fixed/revised ceiling prices” of eight formulations under DPCO, 2013.

The prices of essential drugs are fixed on the basis of the simple average of all medicines in a particular therapeutic segment, having sales of more than 1 per cent. Companies are allowed to hike prices of such drugs by up to 10 per cent in a year.


Guide to approaching a consumer court

India's first practical guide to resolving your complaints by approaching consumer court. Guidance
Customer Complaint


Enter your email address to subscribe to our Newsletter.